Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 567

1.

Targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid prevents murine lupus nephritis.

Wu T, Ye Y, Min SY, Zhu J, Khobahy E, Zhou J, Yan M, Hemachandran S, Pathak S, Zhou XJ, Andreeff M, Mohan C.

Arthritis Rheumatol. 2014 Jul 21. doi: 10.1002/art.38782. [Epub ahead of print]

PMID:
25047252
[PubMed - as supplied by publisher]
2.

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.

Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M.

Br J Haematol. 2014 Jun 19. doi: 10.1111/bjh.12978. [Epub ahead of print]

PMID:
24942980
[PubMed - as supplied by publisher]
3.

Role of integrin alpha4 in drug resistance of leukemia.

Shishido S, Bönig H, Kim YM.

Front Oncol. 2014 May 23;4:99. doi: 10.3389/fonc.2014.00099. eCollection 2014. Review.

PMID:
24904821
[PubMed]
Free PMC Article
4.

The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.

Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N Jr, Konopleva M, Calin G, Kornblau SM, Andreeff M.

Biochim Biophys Acta. 2014 Sep;1843(9):1969-77. doi: 10.1016/j.bbamcr.2014.05.006. Epub 2014 May 21.

PMID:
24858343
[PubMed - in process]
5.

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.

Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K.

Cancer Sci. 2014 Jul;105(7):795-801. doi: 10.1111/cas.12430. Epub 2014 Jun 3.

PMID:
24766216
[PubMed - in process]
6.

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.

Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F.

Expert Opin Investig Drugs. 2014 Jul;23(7):943-54. doi: 10.1517/13543784.2014.911839. Epub 2014 Apr 21.

PMID:
24749672
[PubMed - in process]
7.

Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells.

Zhang W, Ruvolo VR, Gao C, Zhou L, Bornmann W, Tsao T, Schober WD, Smith P, Guichard S, Konopleva M, Andreeff M.

Mol Cancer Ther. 2014 Jul;13(7):1848-59. doi: 10.1158/1535-7163.MCT-13-0576. Epub 2014 Apr 16.

PMID:
24739393
[PubMed - in process]
8.

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.

Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE.

Cancer. 2014 Jul 15;120(14):2142-9. doi: 10.1002/cncr.28705. Epub 2014 Apr 15.

PMID:
24737502
[PubMed - in process]
9.

The effect of calcium channel blockers on the outcome of acute myeloid leukemia.

Chae YK, Dimou A, Pierce S, Kantarjian H, Andreeff M.

Leuk Lymphoma. 2014 Apr 29. [Epub ahead of print]

PMID:
24628293
[PubMed - as supplied by publisher]
10.

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.

Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.

PMID:
24619500
[PubMed - in process]
11.

Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102.

Fidler JM, An J, Carter BZ, Andreeff M.

Cancer Chemother Pharmacol. 2014 May;73(5):961-74. doi: 10.1007/s00280-014-2428-6. Epub 2014 Mar 12.

PMID:
24619497
[PubMed - in process]
Free PMC Article
12.

Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.

Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, Ruvolo P, Schober WD, Shpall EJ, Nguyen MH, Strunk D, Bueso-Ramos CE, Konoplev S, Davis RE, Konopleva M, Andreeff M.

Blood. 2014 Apr 24;123(17):2691-702. doi: 10.1182/blood-2013-06-511527. Epub 2014 Mar 5.

PMID:
24599548
[PubMed - indexed for MEDLINE]
13.

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.

Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R.

Blood. 2014 Apr 10;123(15):2412-5. doi: 10.1182/blood-2013-10-532374. Epub 2014 Mar 4.

PMID:
24596420
[PubMed - indexed for MEDLINE]
14.

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G.

J Clin Invest. 2014 Apr 1;124(4):1512-24. doi: 10.1172/JCI70921. Epub 2014 Mar 3.

PMID:
24590286
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM.

Clin Cancer Res. 2014 Apr 15;20(8):2226-35. doi: 10.1158/1078-0432.CCR-13-1978. Epub 2014 Feb 28.

PMID:
24583795
[PubMed - in process]
16.

Acute pericarditis.

Andreeff RA.

JAAPA. 2014 Mar;27(3):49-50. doi: 10.1097/01.JAA.0000443970.76975.97. No abstract available.

PMID:
24566345
[PubMed - in process]
17.

Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M.

J Natl Cancer Inst. 2014 Feb;106(2):djt440. doi: 10.1093/jnci/djt440.

PMID:
24526787
[PubMed - indexed for MEDLINE]
18.

Quantitative analysis of regional lung ventilation and perfusion PET with (68)Ga-labelled tracers.

Oehme L, Zöphel K, Golgor E, Andreeff M, Wunderlich G, Brogsitter C, de Abreu MG, Kotzerke J.

Nucl Med Commun. 2014 May;35(5):501-10. doi: 10.1097/MNM.0000000000000084.

PMID:
24509518
[PubMed - in process]
19.

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.

Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H.

Leukemia. 2014 Jul;28(7):1543-5. doi: 10.1038/leu.2014.54. Epub 2014 Feb 3. No abstract available.

PMID:
24487412
[PubMed - in process]
20.

Higher levels of spontaneous breathing induce lung recruitment and reduce global stress/strain in experimental lung injury.

Güldner A, Braune A, Carvalho N, Beda A, Zeidler S, Wiedemann B, Wunderlich G, Andreeff M, Uhlig C, Spieth PM, Koch T, Pelosi P, Kotzerke J, de Abreu MG.

Anesthesiology. 2014 Mar;120(3):673-82. doi: 10.1097/ALN.0000000000000124.

PMID:
24406799
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk